Pfizer suppressed more damning information about the vaccine. Three MDs.
Report 66: 1,077 Immune-Mediated/Autoimmune Adverse Events in First 90 Days of Pfizer mRNA “Vaccine” Rollout, Including 12 Fatalities. Pfizer Undercounted This Category of Adverse Events by 270 Occurrences.
April 13, 2023 • by Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt
The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote an important review of immune-mediated/autoimmune adverse events found in Pfizer document
5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “
5.3.6“). This category is comprised of the numerous diseases resulting from disordered immune attacks against tissues of any of the body’s organs. However, it excludes anaphylaxis which has its own
separate report, as well as autoimmune diseases attaching nerve tissue (e.g., Guillain-Barré), which have been explored in other 5.3.6 neurological and musculoskeletal
reports.
It is important to note that the adverse events (AEs) in the
5.3.6 document were reported to Pfizer for
only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.
Highlights of this report include:
- Twelve immune-mediated/autoimmune adverse events were fatal.
- Of adverse events with gender specified, 77% (526) were female, and 23% (156) were male – a female to male ratio of 3.4 to 1.
- Ages of affected patients were 19% elderly, 71% adult, <1% adolescent, and 10% not reported.
- Time from vaccination to onset was given for 75% of events with a range of 24 hours to 30 days. Half started within 24 hours of injection.
- Only immune-mediated/autoimmune diseases or conditions with over 10 cases are included in Pfizer’s reporting, leaving out 270 adverse events of this type. Thus, adverse events in this category were undercounted by Pfizer.
- Adverse events in this group include:
- Hypersensitivity (which is not further defined, though it accounts for 55% of the AEs.
- Peripheral neuropathy, which often causes weakness, numbness and pain, usually in the hands and feet, and can also affect other areas and body functions including digestion, urination, and circulation.
- Pericarditis (inflammation of the lining of the heart).
- Myocarditis (immune attack against the heart muscle).
- Encephalitis (brain inflammation disorders).
- Diabetes.
- Psoriasis.
- Dermatitis.
- Blistering Skin disorder.
- Autoimmune disorder.
- Raynaud’s phenomenon.
- Immune rejection of transplanted organs was not mentioned whether from there being zero instances of it or, perhaps, because there were 10 or fewer instances.
Pfizer concluded, “This cumulative case review does not raise new safety issues. Surveillance will continue.” However, as of the date of this report, 25.5 months after the completion of Pfizer’s post-marketing analysis, no additional safety data has been released to the public.
View attachment 10816
View attachment 10817
